Financial Performance - The company's operating revenue for Q1 2024 was RMB 324,809,103.67, representing a decrease of 12.07% compared to the same period last year[3]. - The net profit attributable to shareholders of the listed company was a loss of RMB 272,222,474.99, a decline of 244.98% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 280,666,741.34, down 251.92% year-on-year[3]. - The total revenue for Q1 2024 was CNY 324,809,103.67, a decrease of 12.0% compared to CNY 369,386,010.95 in Q1 2023[21]. - Net profit for Q1 2024 was a loss of CNY 273,363,603.07, compared to a profit of CNY 187,710,078.62 in Q1 2023[22]. - The total comprehensive income for Q1 2024 was a loss of CNY 272,499,809.53, compared to a profit of CNY 183,307,433.87 in Q1 2023[24]. - Basic earnings per share decreased by 244.00%[10]. - Diluted earnings per share also decreased by 244.00%[10]. - Basic earnings per share for Q1 2024 was CNY -0.36, compared to CNY 0.25 in Q1 2023[24]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 9,733,254,487.30, a decrease of 2.93% from the end of the previous year[4]. - The equity attributable to shareholders of the listed company was RMB 7,993,144,600.58, down 3.46% from the end of the previous year[4]. - The company's total liabilities as of March 31, 2024, were RMB 1.74 billion, compared to RMB 1.75 billion at the end of the previous period, indicating a decrease of about 0.3%[19]. - The company's total equity attributable to shareholders decreased to CNY 7,993,144,600.58 from CNY 8,279,315,724.35 as of December 31, 2023[20]. - The company's total assets decreased from RMB 10.03 billion to RMB 9.73 billion, a decline of about 3%[18]. Cash Flow - The net cash flow from operating activities was RMB 119,953,519.31, not applicable for year-on-year comparison[3]. - The company reported a decrease in cash flow from operating activities due to reduced payments for experimental models[10]. - In Q1 2024, the cash inflow from operating activities was 492,589,961.10, a decrease of 22.4% compared to 635,825,537.05 in Q1 2023[27]. - The net cash flow from operating activities in Q1 2024 was 119,953,519.31, a significant improvement from a negative cash flow of –13,668,184.06 in Q1 2023[28]. - The cash inflow from investment activities in Q1 2024 was 111,453,520.72, down 50.0% from 222,354,944.59 in Q1 2023[29]. - The net cash flow from investment activities in Q1 2024 was –67,562,298.65, compared to a positive cash flow of 106,476,212.61 in Q1 2023[29]. - The cash outflow from financing activities in Q1 2024 was 37,928,364.49, an increase from 24,852,351.87 in Q1 2023[30]. - The net cash flow from financing activities in Q1 2024 was –37,928,364.49, worsening from –24,852,351.87 in Q1 2023[30]. - The cash and cash equivalents at the end of Q1 2024 amounted to 2,865,314,156.35, a decrease from 2,961,151,889.94 at the end of Q1 2023[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 74,233[11]. - The top ten shareholders held a total of 22.29% of shares, with the largest shareholder holding 167,160,633 shares[11]. Business Operations - The laboratory services business contributed a net profit of RMB -21,043,700, a decline of 130.01% year-on-year[5]. - The company signed new contracts worth RMB 400 million during the reporting period, with the number of new projects increasing by approximately 20% year-on-year, resulting in a total backlog of RMB 3.38 billion[15]. - The company emphasized the importance of monitoring investment risks due to various factors affecting order execution[15]. Non-Recurring Items - The company reported non-recurring gains and losses of RMB 8,444,300 for the reporting period[6]. - Non-recurring gains and losses amounted to a total of -82,637.33 and -558,720.76 respectively, with a tax impact of 1,422,161.37[8]. - The company has not identified any significant non-recurring gains or losses beyond those listed in the regulatory announcement[8]. Research and Development - The company reported a significant increase in research and development expenses, totaling CNY 22,967,298.39 in Q1 2024, down from CNY 27,611,585.58 in Q1 2023[21]. Fair Value Changes - The fair value change of biological assets resulted in a net loss of RMB 284,048,900[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 251.92%, primarily due to reduced net profit from laboratory services and losses from changes in the fair value of biological assets[10]. Other Comprehensive Income - Other comprehensive income for Q1 2024 showed a net amount of CNY 863,793.54, compared to a loss of CNY -4,402,644.75 in Q1 2023[23]. - Investment income for Q1 2024 was CNY 6,972,038.25, a significant increase from CNY 514,120.05 in Q1 2023[22].
昭衍新药(06127) - 2024 Q1 - 季度业绩